PMID- 35804390
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20220716
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Jul 8
TI  - A signature of immune-related gene pairs (IRGPs) for risk stratification and 
      prognosis of oral cancer patients.
PG  - 227
LID - 10.1186/s12957-022-02630-1 [doi]
LID - 227
AB  - BACKGROUND: With low response to present immunotherapy, it is imperative to 
      identify new immune-related biomarkers for more effective immunotherapies for 
      oral cancer. METHODS: RNA profiles for 390 oral cancer patients and 32 normal 
      samples were downloaded from The Cancer Genome Atlas (TCGA) database and 
      differentially expressed genes (DEGs) were analyzed. Immune genesets from ImmPort 
      repository were overlapped with DEGs. After implementing univariate Cox analysis 
      and the least absolute shrinkage and selection operator (LASSO) Cox regression 
      analysis, key immune-related gene pairs (IRGPs) among the overlapped DEGs for 
      predicting the survival risk were obtained. Then, the cutoff of risk score was 
      calculated by the receiver operating characteristic (ROC) curve to stratify oral 
      cancer patients into high and low-risk groups. Multivariate Cox analysis was used 
      to analyze independent prognostic indicators for oral cancer. Besides, 
      infiltration of immune cells, functional annotation, and mutation analysis of 
      IRGPs were conducted. Biological functions correlated with IRGPs were enriched by 
      Gene Set Enrichment Analysis (GSEA) method. RESULTS: We identified 698 
      differentially expressed genes (DEGs) in response to oral cancer. 17 IRGPs among 
      the DEGs were identified and integrated into a risk score model. Patients in the 
      high-risk group have a significantly worse prognosis than those in the low-risk 
      group in both training (P<0.001) and test (P=0.019) cohorts. Meanwhile, the IRGP 
      model was identified as an independent prognostic factor for oral cancer. 
      Different infiltration patterns of immune cells were found between the high- and 
      low-risk groups that more types of T and B cells were enriched in the low-risk 
      group. More immune-related signaling pathways were highly enriched in the 
      low-risk group and Tenascin C (TNC) was the most frequently mutated gene. We have 
      developed a novel 17-IRGPs signature for risk stratification and prognostic 
      prediction of oral cancer. CONCLUSION: Our study provides a foundation for 
      improved immunotherapy and prognosis and is beneficial to the individualized 
      management of oral cancer patients.
CI  - (c) 2022. The Author(s).
FAU - Yu, Yanling
AU  - Yu Y
AD  - Department of Stomatology, Weihai Central Hospital, Weihai, China.
FAU - Tian, Jing
AU  - Tian J
AD  - Department of Stomatology, Feicheng Hospital Affiliated to Shandong First Medical 
      University, Taian, China.
FAU - Hou, Yanni
AU  - Hou Y
AD  - Department of Special Dental Care Clinic, Wendeng Stomatology Hospital, Weihai, 
      Shandong, China.
FAU - Zhang, Xinxin
AU  - Zhang X
AD  - Department of Stomatology, Feicheng Hospital Affiliated to Shandong First Medical 
      University, Taian, China.
FAU - Li, Linhua
AU  - Li L
AD  - Repair Department of Stomatology, Shouguang Stomatology Hospital, Weifang, China.
FAU - Cong, Peifu
AU  - Cong P
AD  - Department of Stomatology, Weihai Central Hospital, Weihai, China.
FAU - Ji, Lei
AU  - Ji L
AD  - Operating room, Weihai Central Hospital, Weihai, China.
FAU - Wang, Xuri
AU  - Wang X
AD  - Department of Stomatology, Weihai Central Hospital, Weihai, China. 
      wangxuri7@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220708
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Mouth Neoplasms/genetics
MH  - Prognosis
MH  - Risk Assessment/methods
PMC - PMC9264557
OTO - NOTNLM
OT  - Biomarker
OT  - Immune infiltration
OT  - Immunotherapy
OT  - Oral cancer
OT  - Prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/07/09 06:00
MHDA- 2022/07/14 06:00
PMCR- 2022/07/08
CRDT- 2022/07/08 23:47
PHST- 2022/01/07 00:00 [received]
PHST- 2022/05/06 00:00 [accepted]
PHST- 2022/07/08 23:47 [entrez]
PHST- 2022/07/09 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/07/08 00:00 [pmc-release]
AID - 10.1186/s12957-022-02630-1 [pii]
AID - 2630 [pii]
AID - 10.1186/s12957-022-02630-1 [doi]
PST - epublish
SO  - World J Surg Oncol. 2022 Jul 8;20(1):227. doi: 10.1186/s12957-022-02630-1.